OBR Daily Commentary

forumImage

Lung Cancer Patients May Benefit From Delayed Chemotherapy After Surgery

(Yale Cancer Center) Jan 5, 2017 - A new Yale study suggests that patients with a common form of lung cancer may still benefit from delayed chemotherapy started up to four months after surgery, according to the researchers. The study was published online by JAMA Oncology on Jan. 5, 2017.

Read Article arrow

H. Jack West, MD (Posted: January 06, 2017)

quotesAn important finding from the National Cancer Database, the report by Boffa and colleagues reveals that patients who start adjuvant chemo more than 8 weeks after chemo and even months later follow an improved survival comparable to that seen in patients who received adjuvant chemo starting within the target of 5-7 weeks following surgery, both groups having a superior survival compared to those who undergo surgery alone. This is valuable to know because the clinical trials of adjuvant chemotherapy for resected NSCLC included patients who are disproportionately younger and more fit than we see in many real world clinics, and many patients experience complications and slower recovery. This leaves us able to consider adjuvant chemo only after a delay, and we have been left with only our judgment about whether that is helpful. Though retrospective, these data help answer that question and corroborate the finding of a benefit of adjuvant chemo in a broader real world clinical experience than studied in prospective trials with arguably non-representative patients, and they also suggest that we should extrapolate the favorable results of early administration of adjuvant chemo for patients who present to us beyond 7 weeks post-op.quotes

Add Comment 1 Comment
forumImage

Pfizer Joins Forces with IBM on Immuno-oncology Drug Discovery

(PMLiVE [UK]) Dec 21, 2016 - Engages the Watson supercomputer to accelerate research into new cancer therapies.

Read Article arrow

H. Jack West, MD (Posted: December 22, 2016)

quotesApplying artificial intelligence to immunotherapy efforts is like nuclear fission for hype... I hope it doesn't break the internet.quotes

Add Comment 1 Comment
forumImage

Results From 3AURA Trial Show Osimertinib Reduces Risk of Disease Progression by 70 Percent in Patients With Non-Small Cell Lung Cancer

(IASLC) Dec 6, 2016 - Patients with non-small cell lung cancer on osimertinib experienced a higher rate of progression-free disease than patients enrolled in a control group that received only chemotherapy, according to research presented at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Read Article arrow

H. Jack West, MD (Posted: December 08, 2016)

quotesOsimertinib was overwhelmingly superior to chemotherapy in terms of both efficacy and tolerability in T790M mutation-positive acquired resistance after initial EGFR TKI therapy. There should be no question that osimertinib represents the optimal treatment approach here for such patients. Nevertheless, testing rates for EGFR TKI in the setting of acquired resistance remains only 30-40% in the US, far lower than it should be. With osimertinib restricted to T790M-posive patients, it is incumbent on oncologists to look for it, whether in tissue or in plasma followed by tissue if negative by plasma testing. To fail to test for T790M should be considered substandard care.quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Professor and Chair, Department of Radiation Oncology...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Health Policy
member photo
Joseph Bailes, MD

National Health Policy Expert...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Professor and Physician-in-Chief of the Ohios State Uni...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...